Ebastin Brown (Ebastine 10 mg)
Second-generation antihistamine for allergic rhinitis and chronic urticaria
Quick facts about Ebastin Brown
Key Takeaways About Ebastin Brown
- Non-sedating antihistamine: Ebastin Brown causes significantly less drowsiness than first-generation antihistamines such as diphenhydramine or chlorpheniramine
- Once-daily dosing: The long half-life of the active metabolite carebastine (15-19 hours) allows convenient once-daily administration
- Dual indication: Effective for both allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives)
- Drug interaction caution: CYP3A4 inhibitors such as ketoconazole and erythromycin can significantly increase ebastine blood levels and should be used with caution
- Prescription required: Ebastin Brown requires a valid prescription from a licensed healthcare provider
What Is Ebastin Brown and What Is It Used For?
Ebastin Brown is a prescription second-generation antihistamine containing ebastine 10 mg. It is used to relieve the symptoms of allergic rhinitis (hay fever) including sneezing, runny nose, itchy eyes, and nasal congestion, as well as chronic idiopathic urticaria (hives) characterized by itchy wheals on the skin.
Ebastine, the active ingredient in Ebastin Brown, belongs to the class of second-generation H1-receptor antagonists. These medications work by selectively blocking histamine from binding to H1 receptors on cells throughout the body, particularly in the nasal mucosa, skin, and eyes. When allergens such as pollen, dust mites, or pet dander trigger an immune response, the body releases histamine, which causes the familiar symptoms of allergic reactions: sneezing, rhinorrhea (runny nose), nasal congestion, itchy and watery eyes, and skin hives.
Unlike first-generation antihistamines (such as diphenhydramine, chlorpheniramine, or hydroxyzine), ebastine has a high selectivity for peripheral H1 receptors and minimal ability to cross the blood-brain barrier. This pharmacological profile means that Ebastin Brown provides effective allergy relief while causing significantly less sedation and cognitive impairment. This distinction is clinically important for patients who need to maintain alertness during daily activities, driving, or operating machinery.
After oral administration, ebastine is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism by the cytochrome P450 enzyme CYP3A4 in the liver. The primary active metabolite is carebastine, which is responsible for most of the drug's antihistaminic activity. Carebastine reaches peak plasma concentrations within 2 to 4 hours and has an elimination half-life of approximately 15 to 19 hours, which supports the convenience of once-daily dosing.
Allergic Rhinitis
Allergic rhinitis, commonly known as hay fever, is one of the primary indications for Ebastin Brown. The condition affects an estimated 10-30% of the global population and is triggered by airborne allergens. Seasonal allergic rhinitis is caused by pollens from trees, grasses, and weeds, while perennial allergic rhinitis is triggered by year-round allergens such as dust mites, mold spores, and animal dander. Ebastin Brown effectively reduces sneezing, rhinorrhea, nasal itching, and ocular symptoms (itchy, watery, red eyes) associated with both forms of allergic rhinitis.
Chronic Idiopathic Urticaria
Chronic idiopathic urticaria (CIU) is characterized by recurrent episodes of itchy wheals (hives) that persist for six weeks or longer without an identifiable external trigger. This condition significantly impairs quality of life due to persistent itching and the unpredictable appearance of skin lesions. Ebastin Brown helps control the itching (pruritus) and reduces the number and size of wheals. International guidelines, including those from the European Academy of Allergy and Clinical Immunology (EAACI) and the World Allergy Organization (WAO), recommend second-generation H1-antihistamines as first-line treatment for chronic urticaria.
Ebastin Brown is a symptomatic treatment that relieves allergy symptoms but does not cure the underlying allergic condition. For long-term management of allergies, your doctor may recommend additional strategies such as allergen avoidance, nasal corticosteroids, or allergen immunotherapy.
What Should You Know Before Taking Ebastin Brown?
Before taking Ebastin Brown, inform your doctor about any liver disease, heart rhythm problems (especially QT prolongation), low potassium levels, or if you are taking other medications that inhibit the CYP3A4 enzyme. Ebastin Brown is not recommended during pregnancy or breastfeeding unless specifically advised by your doctor.
As with all prescription medications, it is essential to discuss your complete medical history and current medications with your healthcare provider before starting Ebastin Brown. Certain medical conditions and drug combinations may require dose adjustments, additional monitoring, or selection of an alternative antihistamine.
Contraindications
Ebastin Brown should not be taken if you have a known hypersensitivity (allergy) to ebastine or any of the excipients (inactive ingredients) in the tablet formulation. Additionally, ebastine is contraindicated in patients with:
- Severe hepatic (liver) impairment: Ebastine is extensively metabolized in the liver, and impaired hepatic function can lead to significantly elevated drug levels, increasing the risk of adverse effects including cardiac arrhythmias
- Known QT prolongation: Patients with congenital long QT syndrome or a history of QT prolongation should not take ebastine, as elevated plasma levels may further prolong the QT interval
- Clinically significant hypokalemia: Low potassium levels increase the risk of cardiac arrhythmias when combined with drugs that may affect the QT interval
Warnings and Precautions
Special caution is warranted in several clinical situations. Patients with mild to moderate hepatic impairment may require dose adjustment or more frequent monitoring, as reduced liver function can slow the metabolism of ebastine and increase circulating drug levels. Similarly, patients with significant renal impairment should use ebastine with caution, although dose adjustment is generally not required for mild to moderate kidney disease.
Patients with pre-existing cardiac conditions, particularly those with a history of arrhythmias or those taking other QT-prolonging medications, should be carefully evaluated before prescribing ebastine. While the standard 10 mg dose has not been associated with clinically significant QT prolongation in healthy volunteers, higher doses or impaired metabolism may pose a risk.
Ebastine should be used with caution in elderly patients, who may be more susceptible to adverse effects due to age-related changes in hepatic and renal function. Although ebastine is generally well tolerated in older adults, lower doses may be appropriate in some cases.
Do not exceed the prescribed dose of Ebastin Brown. Taking higher doses than recommended, particularly in combination with CYP3A4 inhibitors (such as ketoconazole or erythromycin), has been associated with QT prolongation on electrocardiogram. Always follow your doctor's dosage instructions carefully.
Pregnancy and Breastfeeding
There is limited clinical data on the use of ebastine during pregnancy. Animal reproduction studies have not demonstrated direct harmful effects on the fetus at therapeutic doses; however, as with most medications, the use of ebastine during pregnancy is generally not recommended unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Pregnant women or those planning pregnancy should discuss alternative treatment options with their healthcare provider.
It is not known whether ebastine or its active metabolite carebastine is excreted in human breast milk. Animal studies have shown that ebastine and its metabolites are present in the milk of lactating animals. Therefore, a decision should be made whether to discontinue breastfeeding or to discontinue ebastine therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Consult your doctor for personalized advice.
Driving and Operating Machinery
At the recommended dose of 10 mg once daily, Ebastin Brown has not been shown to impair driving performance or psychomotor function in controlled clinical studies. However, individual responses may vary, and some patients may experience mild drowsiness or dizziness. It is advisable to assess your individual response to the medication before driving or operating heavy machinery, particularly when starting treatment or after a dose increase.
How Does Ebastin Brown Interact with Other Drugs?
Ebastin Brown is metabolized by the liver enzyme CYP3A4. Drugs that inhibit this enzyme (such as ketoconazole, erythromycin, and itraconazole) can significantly increase ebastine blood levels and should be used with caution. Grapefruit juice should also be avoided as it inhibits CYP3A4.
Drug interactions with ebastine primarily occur through inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for the first-pass metabolism of ebastine to its active metabolite carebastine. When CYP3A4 is inhibited, ebastine plasma levels increase substantially, which may lead to an increased risk of cardiac adverse effects, particularly QT interval prolongation. Understanding these interactions is essential for safe use of Ebastin Brown.
Additionally, while second-generation antihistamines like ebastine cause minimal central nervous system depression on their own, combining them with other sedating substances (such as alcohol, benzodiazepines, or opioid analgesics) may potentiate sedative effects. Patients should be counseled to limit alcohol consumption while taking Ebastin Brown.
Major Interactions
| Drug | Class | Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | Azole antifungal | Strong CYP3A4 inhibitor; significantly increases ebastine levels | Avoid combination or use with close monitoring |
| Itraconazole | Azole antifungal | Strong CYP3A4 inhibitor; increases ebastine exposure | Avoid combination or use with close monitoring |
| Erythromycin | Macrolide antibiotic | Moderate CYP3A4 inhibitor; may increase ebastine levels and QT risk | Use with caution; consider alternative antibiotic |
| Clarithromycin | Macrolide antibiotic | Strong CYP3A4 inhibitor; risk of elevated ebastine levels | Avoid combination; use azithromycin as alternative |
| Ritonavir | HIV protease inhibitor | Potent CYP3A4 inhibitor; markedly increases ebastine exposure | Avoid combination; select a different antihistamine |
Minor Interactions
| Drug / Substance | Effect | Recommendation |
|---|---|---|
| Rifampicin | CYP3A4 inducer; may reduce ebastine efficacy | Monitor for reduced antihistamine effect |
| Grapefruit juice | Inhibits intestinal CYP3A4; may increase ebastine absorption | Avoid grapefruit juice while taking Ebastin Brown |
| Alcohol | May potentiate any sedative effect of ebastine | Limit alcohol consumption during treatment |
| Diazepam | No significant pharmacokinetic interaction, but additive sedation possible | Use with caution; monitor for increased drowsiness |
| Cimetidine | Weak CYP3A4 inhibitor; modest increase in ebastine levels | Generally safe; no dose adjustment typically needed |
Always provide your healthcare provider and pharmacist with a complete list of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are taking. This helps prevent potentially dangerous drug interactions and ensures the safe use of Ebastin Brown.
What Is the Correct Dosage of Ebastin Brown?
The standard adult dose of Ebastin Brown is one 10 mg film-coated tablet taken once daily, with or without food. The dose may be increased to 20 mg once daily by your doctor if symptoms are not adequately controlled at the lower dose.
Dosage of Ebastin Brown should be individualized based on the patient's age, severity of symptoms, response to treatment, and any underlying medical conditions. The following dosage guidelines are based on regulatory approvals and clinical evidence. Always follow your prescribing doctor's specific instructions, as they may differ based on your individual circumstances.
Adults
Standard Adult Dosage
Allergic rhinitis and chronic urticaria: 10 mg (one tablet) once daily. The tablet should be swallowed whole with a glass of water. It can be taken at any time of day, with or without food, although taking it at the same time each day helps maintain consistent blood levels.
If symptoms persist: Your doctor may increase the dose to 20 mg once daily. Do not increase the dose on your own without medical advice.
Children
Pediatric Dosage
Children aged 12 years and older: The same adult dose applies — 10 mg once daily.
Children aged 6 to 11 years: A reduced dose of 5 mg (half a tablet) once daily may be prescribed by a physician. Oral syrup formulations of ebastine, where available, may be preferred for children in this age group for more accurate dosing.
Children under 6 years: Ebastin Brown 10 mg tablets are not recommended for children under 6 years of age due to insufficient clinical data on safety and efficacy in this age group.
Elderly
Geriatric Dosage
No specific dose adjustment is generally required for elderly patients based on age alone. However, since hepatic and renal function may be reduced in older adults, careful monitoring is recommended, and a lower starting dose may be considered at the prescriber's discretion. Elderly patients may also be more susceptible to anticholinergic side effects, although these are rare with second-generation antihistamines.
Hepatic and Renal Impairment
Dose Adjustments for Organ Impairment
Mild to moderate hepatic impairment: A reduced dose or less frequent dosing may be necessary. Your doctor will determine the appropriate regimen based on the severity of liver dysfunction.
Severe hepatic impairment: Ebastin Brown is contraindicated due to the risk of significantly elevated drug levels and potential cardiac adverse effects.
Renal impairment: No dose adjustment is generally required for patients with mild to moderate renal impairment. Limited data are available for severe renal impairment; use with caution and under medical supervision.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (18+) | 10 mg | Once daily | May increase to 20 mg if needed |
| Adolescents (12-17) | 10 mg | Once daily | Same as adult dose |
| Children (6-11) | 5 mg | Once daily | Half a tablet; syrup preferred where available |
| Children (<6) | Not recommended | - | Insufficient safety data |
| Elderly | 10 mg | Once daily | Consider lower dose if hepatic/renal impairment |
| Hepatic impairment (severe) | Contraindicated | - | Risk of elevated drug levels |
Missed Dose
If you miss a dose of Ebastin Brown, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a forgotten tablet. If you frequently forget doses, consider setting a daily alarm or using a pill organizer to help you remember.
Overdose
In the event of an accidental overdose, symptoms may include drowsiness, headache, dry mouth, nausea, and potentially cardiac effects such as tachycardia or QT prolongation at very high doses. There is no specific antidote for ebastine overdose. Treatment is symptomatic and supportive, with particular attention to cardiac monitoring. If you suspect an overdose, contact your local poison control center or seek emergency medical attention immediately.
If you or someone else has taken more Ebastin Brown than prescribed, seek emergency medical help immediately. Bring the medication packaging with you so healthcare professionals can identify the drug and dose taken.
What Are the Side Effects of Ebastin Brown?
Ebastin Brown is generally well tolerated. The most common side effects include headache, dry mouth, and drowsiness. Serious side effects are rare but may include cardiac arrhythmias (particularly QT prolongation) at elevated drug levels. Most patients experience no significant adverse effects at the standard 10 mg dose.
Like all medications, Ebastin Brown can cause side effects, although not everybody experiences them. Clinical trials have demonstrated that ebastine 10 mg is well tolerated, with an adverse event profile similar to placebo in many studies. The following list categorizes side effects by frequency, based on data from clinical trials and post-marketing surveillance.
Side effects are classified according to their frequency of occurrence using the standard medical terminology: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people).
Common Side Effects
Affects 1 in 10 to 1 in 100 patients
- Headache
- Dry mouth (xerostomia)
- Drowsiness or somnolence
- Fatigue
Uncommon Side Effects
Affects 1 in 100 to 1 in 1,000 patients
- Dizziness
- Nausea
- Abdominal pain
- Dyspepsia (indigestion)
- Insomnia
- Rhinitis (paradoxical nasal symptoms)
- Pharyngitis (sore throat)
Rare Side Effects
Affects fewer than 1 in 1,000 patients
- Palpitations
- Tachycardia (rapid heart rate)
- QT prolongation (usually at elevated doses)
- Allergic skin reactions (rash, urticaria)
- Anaphylaxis (extremely rare)
- Elevated liver enzymes
- Myalgia (muscle pain)
- Menstrual irregularities
Most side effects are mild and transient, resolving on their own as your body adjusts to the medication. Common side effects such as headache and dry mouth are typically manageable and rarely require discontinuation of treatment. Drowsiness, while less frequent than with first-generation antihistamines, may occur in some patients, particularly during the first few days of treatment.
Serious cardiac side effects, including QT prolongation and arrhythmias, are primarily associated with elevated ebastine plasma levels caused by CYP3A4 inhibition or hepatic impairment, rather than with the standard 10 mg dose in patients with normal drug metabolism. For this reason, adherence to prescribed doses and avoidance of interacting drugs are critical safety measures.
Seek medical attention promptly if you experience palpitations, an unusually fast or irregular heartbeat, fainting, severe dizziness, or any signs of an allergic reaction (such as difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin rash). These could indicate a serious adverse reaction requiring immediate medical evaluation.
How Should You Store Ebastin Brown?
Store Ebastin Brown at room temperature below 25°C (77°F), in the original packaging, protected from moisture and direct sunlight. Keep all medicines out of reach and sight of children.
Proper storage of Ebastin Brown is essential to maintain the medication's effectiveness and safety throughout its shelf life. Film-coated tablets are designed to protect the active ingredient from degradation, but environmental factors can still affect the quality of the product over time.
Store the tablets at room temperature, ideally between 15°C and 25°C (59°F to 77°F). Do not refrigerate or freeze the tablets. Keep them in the original blister packaging until ready to take, as this provides protection against moisture and light. Avoid storing the medication in the bathroom or near the kitchen sink, where humidity levels are typically higher.
Do not use Ebastin Brown after the expiry date printed on the packaging (marked “EXP”). The expiry date refers to the last day of the stated month. Once the expiry date has passed, return unused tablets to a pharmacy for safe disposal. Do not dispose of medications via household waste or wastewater, as this can harm the environment.
If you notice any visible changes in the appearance of the tablets, such as discoloration, crumbling, or an unusual odor, do not take them. Consult your pharmacist for advice and obtain a replacement supply.
What Does Ebastin Brown Contain?
Each Ebastin Brown film-coated tablet contains 10 mg of ebastine as the active ingredient. The tablets also contain excipients (inactive ingredients) that are necessary for the manufacturing process, stability, and appearance of the formulation.
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. The active and inactive ingredients in Ebastin Brown are listed below.
Active Ingredient
Ebastine 10 mg — a selective, second-generation H1-receptor antagonist (antihistamine). Ebastine acts by blocking histamine at peripheral H1 receptors, preventing the allergic cascade that leads to symptoms such as sneezing, itching, rhinorrhea, and wheals.
Excipients (Inactive Ingredients)
The excipients typically found in ebastine film-coated tablet formulations include:
- Microcrystalline cellulose — used as a filler and binder to give the tablet its structure
- Maize starch (corn starch) — acts as a disintegrant to help the tablet break apart in the gastrointestinal tract
- Lactose monohydrate — used as a filler; patients with lactose intolerance or galactose malabsorption should consult their doctor
- Sodium starch glycolate — a superdisintegrant that promotes rapid tablet dissolution
- Magnesium stearate — a lubricant used during the tablet compression process
- Hypromellose (HPMC) — used in the film coating to protect the tablet and improve swallowability
- Titanium dioxide (E171) — a colorant in the film coating that gives the tablet its white or off-white appearance
- Macrogol (polyethylene glycol) — used in the film coating as a plasticizer
Ebastin Brown tablets may contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to some sugars (including lactose or galactose), or if you have Lapp lactase deficiency or glucose-galactose malabsorption, consult your doctor before taking this medicine.
Frequently Asked Questions About Ebastin Brown
Ebastin Brown is a second-generation antihistamine containing ebastine 10 mg. It is used to treat allergic rhinitis (hay fever) including sneezing, runny nose, nasal congestion and itchy eyes. It is also prescribed for chronic idiopathic urticaria (hives) to relieve itching and reduce the appearance of wheals. Ebastin Brown provides 24-hour symptom relief with once-daily dosing.
Ebastin Brown is a second-generation antihistamine designed to have minimal sedative effects. While drowsiness is uncommon, some patients may experience mild sedation, particularly at higher doses or when combined with other central nervous system depressants. It is significantly less sedating than first-generation antihistamines such as diphenhydramine or chlorpheniramine. If you experience drowsiness, avoid driving or operating machinery until you know how the medication affects you.
Yes, Ebastin Brown can be taken with or without food. Taking it with a high-fat meal may slightly increase the absorption of ebastine, but this does not generally affect its safety or efficacy at the standard dose. For consistent results, try to take it at the same time each day. Importantly, you should avoid consuming grapefruit juice while taking Ebastin Brown, as grapefruit inhibits the CYP3A4 enzyme and may increase drug levels in the blood.
Ebastin Brown typically begins to provide symptom relief within 1 to 3 hours after oral administration. The active metabolite carebastine reaches peak plasma concentrations within 2 to 4 hours. The long elimination half-life of 15 to 19 hours supports once-daily dosing and provides 24-hour symptom coverage for most patients. Maximum therapeutic benefit may take a few days of consistent daily use.
There is limited data on the use of ebastine during pregnancy. Animal studies have not shown direct harmful effects on the fetus, but as a precautionary measure, use during pregnancy is generally not recommended unless the potential benefit justifies the potential risk. Always consult your doctor before taking any medication during pregnancy or while breastfeeding. Your doctor can help weigh the risks and benefits and may recommend alternative treatments.
Ebastin Brown 10 mg tablets are generally approved for use in children aged 12 years and older at the standard adult dose of 10 mg once daily. For children aged 6 to 11 years, a lower dose of 5 mg (half a tablet) may be prescribed by a doctor. Liquid (syrup) formulations may be preferred for younger children where available. Ebastin Brown is not recommended for children under 6 years of age due to insufficient safety and efficacy data. Always follow your doctor's specific dosage instructions.
If you miss a dose of Ebastin Brown, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider setting a daily reminder or using a pill organizer to help maintain consistent dosing.
References
This article is based on peer-reviewed medical literature, international treatment guidelines, and regulatory documentation. All medical claims are supported by evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials) where available.
- European Medicines Agency (EMA). Summary of Product Characteristics: Ebastine film-coated tablets. EMA/CHMP, latest revision. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023. Geneva: WHO; 2023.
- British National Formulary (BNF). Ebastine monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766. doi:10.1111/all.15090
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63 Suppl 86:8-160. doi:10.1111/j.1398-9995.2007.01620.x
- Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;107(4):751-762. doi:10.1067/mai.2001.114238
- Rico S, Antonijoan RM, Barbanoj MJ. Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. J Asthma Allergy. 2009;2:73-92.
- Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol. 1999;55(2):85-93. doi:10.1007/s002280050604
- Sastre J. Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy. 2008;63 Suppl 89:1-20. doi:10.1111/j.1398-9995.2008.01897.x
- U.S. Food and Drug Administration (FDA). Drug Safety Communication: Antihistamines and cardiac risk. Available at: www.fda.gov
Editorial Team
This article was written and medically reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in clinical pharmacology, allergy medicine, and evidence-based medicine.
iMedic Medical Editorial Team — specialists in clinical pharmacology and drug information. All content follows the GRADE evidence framework and international editorial standards.
iMedic Medical Review Board — independent panel of board-certified physicians who verify accuracy, completeness, and adherence to current evidence-based guidelines (EMA, FDA, WHO, BNF).
All medication articles on iMedic are based on official regulatory documentation (EMA SmPC, FDA labeling), peer-reviewed medical literature, and international treatment guidelines. We have no commercial funding and accept no pharmaceutical sponsorship. Content is updated regularly to reflect the latest evidence. Read more about our editorial standards.